[CLAIMS]

[Claim 1]

A brain function improving agent comprising:

at least one of bacterial cells of Lacticaseibacillus paracasei or a processed product of the bacterial cells as an active ingredient.

[Claim 2]

The brain function improving agent according to claim 1, wherein the Lacticaseibacillus paracasei is Lacticaseibacillus paracasei YIT 9029 (FERM BP-1366).

[Claim 3]

The brain function improving agent according to claim 1 or 2, wherein a viable bacterial count of the Lacticaseibacillus paracasei as a daily dose is 10^{10} cfu or more.

[Claim 4]

The brain function improving agent according to claim 1 or 2, wherein a density of the Lacticaseibacillus paracasei per dose is 10^{10} cfu or more/100 mL by viable bacterial count.

[Claim 5]

The brain function improving agent according to claim 1 or 2, wherein the brain function improving agent is at least one of an attentional function improving agent, an arousal improving agent, a response improving

agent to stimulation, or a performance retainer.

[Claim 6]

Use of at least one of bacterial cells of Lacticaseibacillus paracasei or a processed product of the bacterial cells for producing a brain function improving agent.

[Claim 7]

The use according to claim 6, wherein the Lacticaseibacillus paracasei is Lacticaseibacillus paracasei YIT 9029 (FERM BP-1366).

[Claim 8]

Use of Lacticaseibacillus paracasei in the manufacture of a medicament for improving brain functions, wherein the Lacticaseibacillus paracasei is to be orally ingested in an amount of 10^{10} cfu or more/day by viable bacterial count for a continuous period of at least four weeks.

[Claim 9]

The use according to claim 8, wherein the Lacticaseibacillus paracasei is to be ingested in an amount of 10^{10} cfu or more/100 mL by viable bacterial count as a density per dose.

[Claim 10]

The use according to claim 8 or 9, wherein the improving brain functions refers to reducing θ-band

power.

[Claim 11]

The use according to claim 8 or 9, wherein the improving brain functions refers to shortening event-related potential P300 latency.

[Claim 12]

Use of at least one of bacterial cells of Lacticaseibacillus paracasei or a processed product of the bacterial cells for assisting acquisition of event-related potential P300 latency.

[Claim 13]

Lacticaseibacillus paracasei for use in therapy.